Anti-Inflammatory Herbs in Rheumatoid Arthritis: Mechanistic In Vitro Studies and Translational Potential
Published in IJPHDT, Vol-2, Issue-11, Nov-2025 (Vol. 2, Issue 11, 2025)

Keywords
Abstract
Authors (5)
Sivasubramanian P
SNS College of Pharmacy and Health Sciences Coimbatore Pin: 641035
View all publications →Harish. V V
SNS College of Pharmacy and Health Sciences Coimbatore Pin: 641035
View all publications →Isaiamuthan.M M
SNS College of Pharmacy and Health Sciences Coimbatore Pin: 641035
View all publications →Download Article
Best for printing and citation
Best for printing and citation
Article Information
- Article ID:
- IJPHD-00000197
- Paper ID:
- IJPHD-01-000197
How to Cite
, S. & , H. & S & Harish. V V & M (2025). Anti-Inflammatory Herbs in Rheumatoid Arthritis: Mechanistic In Vitro Studies and Translational Potential. International Journal of Pharmacognosy and Herbal Drug Technology, 2(11), xx-xx. https://ijphdt.scholarjms.com/articles/82
Article Actions
Article Impact
More from this Issue
Antiviral Potential of Medicinal Plants Against Respiratory Viruses: In Vitro Screening and In Silico Prioritization
Medicinal plants represent a promising source of antiviral agents against respiratory viruses, supported by evidence from in vitro, in vivo, and in silico studies. Key bioactive compounds, including silymarin from Silybum marianum, germacrone from Geranium macrorrhizum, and licochalcone A from Glycyrrhiza glabra, have demonstrated the ability to reduce viral replication, inhibit viral enzymes such as neuraminidase, interfere with viral entry, and modulate host immune signaling pathways, enhancing viral clearance. Traditional multi-herb formulations, including Japanese medicines like Shahakusan and Hochuekkito, also show measurable antiviral activity, reflecting historical therapeutic applications. Despite these promising findings, challenges remain in standardizing extracts, evaluating pharmacokinetics and safety, and bridging in vitro potency to in vivo efficacy. Integrating in silico prioritization with systematic preclinical studies is essential to guide the selection of candidate phytochemicals for clinical translation. Overall, these findings highlight the potential of plant-derived antivirals as safe, effective, and complementary therapeutics for both human and veterinary respiratory viral infections.
Green-Synthesized Metallic Nanoparticles Using Herbal Extracts: Characterization and Antibacterial Efficacy
An uptick in research into green synthesis methods, especially those that make use of plant extracts, can be attributed to the rising need for sustainable and environmentally friendly nanomaterials. Antibacterial activity against Staphylococcus aureus and Escherichia coli was assessed in this study, which also looked at the green manufacture of metallic nanoparticles using Ocimum sanctum herbal extract. Analyses using UV-Visible spectroscopy, FTIR, SEM, and XRD verified the successful production of nanoparticles. S. aureus was more susceptible than E. coli in antibacterial experiments, which showed a noticeable rise in inhibitory zones that was dose dependent. The produced nanoparticles' powerful antibacterial effectiveness was confirmed by statistical analysis employing one-way ANOVA, which showed significant differences (p
Development and Optimization of Sustained-Release Herbal Tablets for Metabolic Syndrome: Formulation, In-Vitro Release and Stability
Metabolic syndrome is a multifactorial disorder that involves hyperglycemia, dyslipidemia, obese patients, and high cardiovascular risk with the need to be treated on a long-lasting basis to provide long-term clinical outcomes. Herbal medicines provide safe multi-targeted therapeutic potential; however, due to their immediate release dosage form the bioavailability is rather inconsistent and less patient compliance is expected. The proposed study endeavored to design and streamline sustained-release (SR) polyherbal tablets utilizing standardized extracts of Gymnema sylvestre, Trigonella foenum-graecum and Curcuma longa towards enhanced management of metabolic syndrome. The 6 formulations (F1-F6) were developed with different concentrations of the polymer and tested in terms of pre-compression, post-compression qualities, in vitro drug release, stability, and in vivo efficacy in STZ induced diabetic rats. F6 was found to have the best physicochemical properties, extended drug release (81% at 12 hours), and stability in accelerated conditions. Fastening in vivo experiments indicated that F6 reduced the level of fasting blood glucose, total cholesterol and triglyceride levels and increased the level of HDL that had the same therapeutic effects as metformin (p